DESCRIPTION (provided by applicant): Entry into mitosis catalyzed by the Cdc2/Cyclin B kinase, which phosphorylates multiple proteins to induce the dramatic cellular rearrangements characteristic of mitosis. When DNA replication is inhibited, a cell cycle checkpoint pathway prevents mitosis through inhibitory phosphorylation of Cdc2 at Y15 and T14. This inhibition involves sustained activity of the Cdc2 Y15-directed kinase, Wee1, as well as suppression of the Cdc2 Y15 phosphatase, Cdc25. We have discovered that a novel G2/M regulator, Hsl7, promotes intranuclear Wee1 degradation, and that the DNA replication checkpoint disrupts Hsl7-Wee1 interactions. In parallel, Cdc25 is inhibited through binding to 14-3-3 protein. Removal of 14-3-3 from Cdc25 is required for its mitotic activation, and we have found that dissociation of the 14-3-3-Cdc25 complex requires phosphorylation of both Cdc25 T138 (which reduces the affinity of 14-3-3 for Cdc25) and intermediate filament proteins (which then bind 14-3-3, thereby serving as an abundant 14-3-3 "sink"). Additionally, we have discovered that a previously described apoptotic inhibitor, Aven, can also regulate mitotic entry and may be important for DNA-responsive checkpoint operation. The objective of this proposal to elucidate both the Wee1 and Cdc25-modulatory arms of DNA-responsive checkpoint pathways with the long term goal of fully understanding the control of M phase entry. Towards this end, we propose to I) Delineate the role of Hsl7 in checkpoint-mediated Wee1 regulation II) Elucidate the mechanism(s) which regulate 14-3-3 release from Cdc25 and III) Determine how Aven regulates mitotic entry.
No Sub Projects information available for 2R01GM067225-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01GM067225-05
Patents
No Patents information available for 2R01GM067225-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01GM067225-05
Clinical Studies
No Clinical Studies information available for 2R01GM067225-05
News and More
Related News Releases
No news release information available for 2R01GM067225-05
History
No Historical information available for 2R01GM067225-05
Similar Projects
No Similar Projects information available for 2R01GM067225-05